My understanding is we shouldn't expect the uplist until the end of February/beginning of March (3 month timeline from date of application).
Which means both Phase 1 cancer studies could potentially be underway before the uplist to NASDAQ.
The SCLC and Pancreatic Cancer studies are targeted for non-dilutive financing (perhaps Grants at minimum of 50% of the cost if not 100%).
The DMT Phase 1 and DMT Phase 2 are the two studies up for a capital raise in 2022. As Chronic Cough will likely not advance in 2022 because of the timing of the IPF/CC data readout in Q2 2022.
My best guesstimate for a capital raise in 2022 is upwards of 10 Million USD.
The big question remains as to when will they pull the trigger and at what price for shares - and if warrants will be attached?
The questions regarding financing, like toxic financing (shares+ warrants) was off the table in the Q&A per the CEO.
News 
Market Data 
Discover 
